The biopharmaceutical company is developing therapeutics to treat neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system diseases, pain, and various types of cancer.
Anavex Life Sciences advancing its Parkinson's disease therapy through the pipeline
Quick facts: Anavex Life Sciences
Market Cap: $142.68 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE